Publication:
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

Simple item page
dc.contributor.authorsDepartment of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey; Aygen, Bilgehan; Demirturk, Nese; Department of Infectious Diseases and Clinical Microbiology, Afyon Kocatepe University School of Medicine, Afyonkarahisar, Turkey; Yildiz, Orhan; Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey; Celen, Mustafa Kemal; Department of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakir, Turkey; Celik, Ilhami; Department of Infectious Diseases and Clinical Microbiology, Saglik Bilimleri University Kayseri Training and Research Hospital, Kayseri, Turkey; Barut, Sener; Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University School of Medicine, Tokat, Turkey; Ural, Onur; Department of Infectious Diseases and Clinical Microbiology, Selcuk University School of Medicine, Konya, Turkey; Batirel, Ayse; Department of Infectious Diseases and Clinical Microbiology, Saglik Bilimleri University Kartal Dr. Lutfu Kirdar Training and Research Hospital, Istanbul, Turkey; Mistik, Resit; Department of Infectious Diseases and Clinical Microbiology, Uludag University School of Medicine, Bursa, Turkey; Simsek, Funda; Department of Infectious Diseases and Clinical Microbiology, Okmeydani Training and Research Hospital, Istanbul, Turkey; Asan, Ali; Department of Infectious Diseases and Clinical Microbiology, Saglik Bilimleri University Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey; Ersoz, Gulden; Department of Infectious Diseases and Clinical Microbiology, Mersin University School of Medicine, Mersin, Turkey; Turker, Nesrin; Department of Infectious Diseases and Clinical Microbiology, Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey; Bilgin, Huseyin; Department of Infectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey; Kinikli, Sami; Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey; Karakecili, Faruk; Department of Infectious Diseases and Clinical Microbiology, Erzincan University School of Medicine, Erzincan, Turkey; Zararsiz, Gokmen; Department of Biostatistics, Erciyes University School of Medicine, Kayseri, Turkey
dc.date.accessioned2022-03-02T05:41:37Z
dc.date.accessioned2026-01-11T15:44:46Z
dc.date.available2022-03-02T05:41:37Z
dc.date.issued2020-05-12
dc.identifier.doi10.5152/tjg.2020.19197
dc.identifier.issn13004948, 21485607
dc.identifier.issue4
dc.identifier.pages305-317
dc.identifier.urihttps://hdl.handle.net/11424/218669
dc.identifier.volume31
dc.language.isoeng
dc.relation.urihttps://www.turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-the-turkey-experience-experience-136659
dc.titleReal-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
dc.title.alternativeReal-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection
dc.typearticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
475.87 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları